Readout Newsletter: Denali, Corcept win FDA approvals

Wish to keep on prime of the science and politics driving biotech right now? Join to get our biotech publication in your inbox.

The FDA granted accelerated approval to Denali’s Hunter syndrome drug, providing sufferers hope after a string of more durable uncommon illness selections. Sarepta, in the meantime, posted early however restricted information on new RNA therapies, asking buyers to purchase again in after a tough 12 months.

Additionally, an approval from Corcept after it had an FDA miss with the identical drug final 12 months, and we await a high-stakes readout from off-the-shelf CAR-T participant Allogene.